Press Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 20, 2018--
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey,
president and chief executive officer, will present at the 30th Annual
Piper Jaffray Healthcare Conference in New York on Wednesday, November
28, 2018 at 2:30 p.m. Eastern Time. The conference is being held at the
Lotte New York Palace Hotel.

A live webcast of the presentation can be accessed by visiting the
investors section of the Company’s website at www.aveooncology.com.
A replay of the webcast will be archived for 30 days following the
presentation date.

About AVEO

AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a
biopharmaceutical company dedicated to advancing a broad portfolio of
targeted medicines for oncology and other areas of unmet medical need.
The Company’s strategy is to retain North American rights to its
oncology portfolio while securing partners in development and
commercialization outside of North America. The Company is seeking to
develop and commercialize its lead candidate tivozanib in North
America as a treatment for advanced or metastatic renal cell carcinoma
(“RCC”). The Company has outlicensed tivozanib (FOTIVDA®) for
oncological indications in Europe and other territories outside of North
America. Tivozanib is approved in the European Union, as well
as Norway and Iceland, for the first-line treatment of adult patients
with RCC and for adult patients who are vascular endothelial growth
factor receptor and mTOR pathway inhibitor-naïve following disease
progression after one prior treatment with cytokine therapy for RCC. The
Company has entered into partnerships for the development and
commercialization of AV-203 (CAN017) and ficlatuzumab, both clinical
stage assets in oncology. The Company is currently seeking a partner to
develop the AV-353 platform, a preclinical asset, worldwide for the
potential treatment of pulmonary arterial hypertension and oncology. In
addition, a new formulation of tivozanib is being explored in ocular
conditions. The Company has recently regained the rights to its AV-380
program for the potential treatment of cachexia and is considering a
variety of options to advance the program’s development.

This press release contains forward-looking statements of AVEO that
involve substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this press release are
forward-looking statements. Actual results or events could differ
materially due to a number of important factors, including risks
discussed in the section titled “Risk Factors” in AVEO’s most recent
Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its
other filings with the SEC. The forward-looking statements in this press
release represent AVEO’s views as of the date of this press release.
AVEO anticipates that subsequent events and developments may cause its
views to change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any
obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any date
other than the date of this press release.